Muscarinic receptors in psychiatric disorders -Can we mimic 'health'?

NeuroSignals

Volumn 17, Issue 4, 2009, Pages 298-310

  Scarr, E ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Bipolar disorder; Depression; Muscarinic receptors; Schizophrenia; Signaling pathways

Indexed keywords

1,6 DIMETHYL 4 (6 NITROBENZO[D][1,3] DIOXOL 5 YL) 2 OXO 1,2,3,4 TETRAHYTETRAHYDROPYRIMIDINE 5 CARBOXYLATE; 2 (4 ETHOXYPHENYLAMINO) N' ((2 HYDROXYNAPHTHALEN 1 YL)METHYLENE)ACETOHYDRAZIDE; 3 AMINO 5 CHLORO 6 METHOXY 4 METHYLTHITHIENO(2,3 B)PYRIDINE 2 CARBOXYLIC ACID CYCLOPROPYLAMIDE; 3 AMINO N (4 METHOXYBENZYL) 4,6 DIMETHYLTHIENO [2,3 B] PYRIDINE CARBOXAMIDE; 3 AMINO N (BENZO[D][1,3]DIOXOL 5 YLMETHYL) 4,6 DIMETHYLTHIENO[2,3 B]PYRIDINE CARBOXAMIDE; 3 AMINO N [(4 CHLOROPHENYL)METHYL] 4,6 DIMETHYLTHIENO[2,3 B]PYRIDINE 2 CARBOXAMIDE; 4 (4 [3 (4 BUTYLPIPERIDIN 1 YL) PROPYL] 7 FLUORO 4H BENZO[1,4]OXAZIN 3 ONE; AC 260584; ACETYLCHOLINE; ACP 104; LY 2033298; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; NEUROLEPTIC AGENT; NEUROMUSCULAR BLOCKING AGENT; NORCLOZAPINE; OXOTREMORINE; PHYSOSTIGMINE; PLACEBO; SCOPOLAMINE; UNCLASSIFIED DRUG; VU 0029767; VU 0090157; VU 0152099; VU 0152100; VU 100010; XANOMELINE;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITION; DEPRESSION; DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; MANIA; NONHUMAN; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACETYLCHOLINE; ANIMALS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; MENTAL DISORDERS; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA;

EID: 70350780200     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000231896     Document Type: Review

References (113)

1. Wessler I, Kirkpatrick C, Racké K: The cholinergic 'pitfall': Acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol 1999; 26: 198-205.
2. Deutsch JA: The cholinergic synapse and the site of memory. Science 1971; 174: 788-794.
3. Mesulam M-M: The cholinergic innervation of the human cerebral cortex; in Descarries L, Krnjevic K, Steriade M (eds): Progress in Brain Research Acetylcholine in the Cerebral Cortex. Amsterdam, Elsevier, 2004, pp 67-78.
4. Perry E, Walker M, Grace J, Perry R: Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22: 273-280.
5. Dale HH: The action of certain esters and ethers of choline and their relation to muscarine. J Pharmacol Exp Ther 1914; 6: 147-190.
6. Steinlein OK, Bertrand D: Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases. Biochem Pharmacol 2008; 76: 1175-1183.
7. Lucas-Meunier E, Fossier P, Baux G, Amar M: Cholinergic modulation of the cortical neuronal network. Pflügers Arch 2003; 446: 17-29.
8. Kristiansen K: Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: Molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 2004; 103: 21-80.
9. Wess J: Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 1996; 10: 69-99.
10. Caulfield MP, Birdsall NJ: International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-290.
11. Scarr E, Dean B: Muscarinic receptors: Do they have a role in the pathology of schizophrenia? J Neurochem 2008; 107: 1188-1195.
12. Langmead CJ, Watson J, Reavill C: Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 2008; 117: 232-243.
13. Wess J, Duttaroy A, Zhang W, Gomeza J, Cui Y, Miyakawa T, Bymaster FP, McKinzie L, Felder CC, Lamping KG, Faraci FM, Deng C, Yamada M: M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels 2003; 9: 279-290.
14. Shelton MK, McCarthy KD: Hippocampal astrocytes exhibit Ca 2+ -elevating muscarinic cholinergic and histaminergic receptors in situ. J Neurochem 2000; 74: 555-563.
15. Zeinstra E, te Riele P, Langlois X, Wilczak N, Leysen J, de Keyser J: Aminergic receptors in astrogliotic plaques from patients with multiple sclerosis. Neurosci Lett 2002; 331: 87-90.
16. Miyakawa T, Yamada M, Duttaroy A, Wess J: Hyperactivity and intact hippocampusdependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 2001; 21: 5239-5250.
17. Shinoe T, Matsui M, Taketo MM, Manabe T: Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J Neurosci 2005; 25: 11194-11200.
18. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ: Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6: 51-58.
19. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S: Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 15312-15317.
20. Salamone JD, Correa M, Carlson BB, Wisniecki A, Mayorga AJ, Nisenbaum E, Nisenbaum L, Felder C: Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sci 2001; 68: 2579-2584.
21. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng C, Wess J: Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 10483-10488.
22. Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C, Nomikos GG: M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: Relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004; 18: 1410-1412.
23. Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG: Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 2003; 8: 673-679.
24. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R, Ogawa M, Chou CJ, Xia B, Crawley JN, Felder CC, Deng CX, Wess J: Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001; 410: 207-212.
25. Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, Yamada M, Wess J: Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci USA 2002; 99: 11452-11457.
26. Forrer GR, Miller JJ: Atropine coma: A somatic therapy in psychiatry. Am J Psychiatry 1958; 115: 455-458.
27. Cohen LH, Thale T, Tissenbaum MJ: Acetylcholine treatment of schizophrenia. Arch Neurol Psychiatry 1944; 51: 171-175.
28. Tandon R, Greden JF: Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989; 46: 745-753.
29. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B: Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2006; 12: 232-246.
30. Rowntree DW, Nevin S, Wilson A: The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry 1950; 13: 47-62.
31. Gershon S, Shaw FH: Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet 1961;i:1371-1374.
32. Janowsky DS, El Yousef MK, Davis JM, Hubbard B, Sekerke HJ: Cholinergic reversal of manic symptoms. Lancet 1972;i:1236-1237.
33. Janowsky DS, El Yousef MK, Davis JM, Sekerke HJ: A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972;ii:632-635.
34. Furey ML, Drevets WC: Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006; 63: 1121-1129.
35. Bolden C, Cusack B, Richelson E: Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992; 260: 576-580.
36. Bennett JP Jr, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH: Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979; 36: 927-934.
37. Owen F, Cross AJ, Crow TJ, Lofthouse R, Poulter M: Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr Scand Suppl 1981; 291: 20-28.
38. Watanabe S, Nishikawa T, Takashima M, Toru M: Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 1983; 33: 2187-2196.
39. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 1999; 64: 2351-2358.
40. Harrison PJ: The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999; 122: 593-624.
41. Dean B, Soulby A, Evin G, Scarr E: Levels of [(3)H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1; Schiz Res 2008; 106: 229-236
42. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B: Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918-925.
43. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E: Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002; 7: 1083-1091.
44. Zavitsanou K, Katsifis A, Mattner F, Xu-Feng H: Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004; 29: 619-625.
45. Deng C, Huang XF: Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 2005; 81: 883-890.
46. Scarr E, Sundram S, Keriakous D, Dean B: Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 2007; 61: 1161-1170.
47. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B: Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation. Biol Psychiatry 2000; 48: 381-388.
48. Dean B, Gray L, Keriakous D, Scarr E: A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus Relat Syst 2004; 2: 287-295.
49. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL: The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1996; 1: 54-58.
50. Crook JM, Dean B, Pavey G, Copolov D: The binding of [ 3 H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 1999; 64: 1761-1771.
51. Newell KA, Zavitsanou K, Jew SK, Huang XF: Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 225-233.
52. Zavitsanou K, Katsifis A, Yu Y, Huang XF: M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 2005; 65: 397-403.
53. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, Egan MF, Coppola R, Weinberger DR: In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003; 160: 118-127.
54. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI: Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995; 64: 1888-1891.
55. Mancama D, Arranz MJ, Landau S, Kerwin R: Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 119: 2-6.
56. Scarr E, Keriakous D, Crossland N, Dean B: No change in cortical muscarinic M2, M3 receptors or [(35)S]GTPgammaS binding in schizophrenia. Life Sci 2006; 78: 1231-1237.
57. Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B: Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 2008 [Epub ahead of print]; DOI: 10.1038/ mp.2008.28.
58. Jositsch G, Papadakis T, Haberberger RV, Wolff M, Wess J, Kummer W: Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 389-395.
59. Mrzljak L, Levey AI, Goldman-Rakic PS: Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: Morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 1993; 90: 5194-5198.
60. Kuczewski N, Aztiria E, Gautam D, Wess J, Domenici L: Acetylcholine modulates cortical synaptic transmission via different muscarinic receptors, as studied with receptor knockout mice. J Physiol 2005; 566: 907-919.
61. Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ: Activation of the genetically defined m1 muscarinic receptor potentiates Nmethyl-D -aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci USA 1998; 95: 11465-11470.
62. Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, Forbes IT, Fry VAH, Hagan JJ, Herdon HJ, Jones GA, Jeggo R, Kew JNC, Mazzali A, Melarange R, Patel N, Pardoe J, Randall AD, Roberts C, Roopun A, Starr KR, Teriakidis A, Wood MD, Whittington M, Wu Z, Watson J: Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 2008; 154: 1104-1115.
63. Wynn JK, Light GA, Breitmeyer B, Nuechterlein KH, Green MF: Event-related gamma activity in schizophrenia patients during a visual backward-masking task. Am J Psychiatry 2005; 162: 2330-2336.
64. Fisahn A, Yamada M, Duttaroy A, Gan JW, Deng CX, McBain CJ, Wess J: Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. Neuron 2002; 33: 615-624.
65. Li Z, Bonhaus DW, Huang M, Prus AJ, Dai J, Meltzer HY: AC260584 (4-[3-(4-butylpiperidin-1-yl) -propyl]-7-f luoro-4H-benzo[ 1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Eur J Pharmacol 2007; 572: 129-137.
66. Lamour Y, Dutar P, Rascol O, Jobert A: Basal forebrain neurons projecting to the rat frontoparietal cortex: Electrophysiological and pharmacological properties. Brain Res 1986; 362: 122-131.
67. Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P, Audinot V, Cistarelli L, Gobert A: S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors. I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2Aadrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. J Pharmacol Exp Ther 1997; 282: 132-147.
68. Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, Rollis D, Drevets M, Gandhi S, Solorio G, Drevets WC: Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006; 63: 741-747.
69. Gibbons AS, Scarr E, McLean CA, Sundram S, Dean B: Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2009; 116: 184-191.
70. Sokolski KN, Demet EM: Increased pupillary sensitivity to pilocarpine in depression. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 253-262.
71. Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J: Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 2002; 22: 1709-1717.
72. Mrzljak L, Levey AI, Belcher S, Goldman-Rakic PS: Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey. J Comp Neurol 1998; 390: 112-132.
73. Allen TGJ, Abogadie FC, Brown DA: Simultaneous release of glutamate and acetylcholine from single magnocellular 'cholinergic' basal forebrain neurons. J Neurosci 2006; 26: 1588-1595.
74. Disney AA, Aoki C: Muscarinic acetylcholine receptors in macaque V1 are most frequently expressed by parvalbumin-immunoreactive neurons. J Comp Neurol 2008; 507: 1748-1762.
75. Salgado H, Bellay T, Nichols JA, Bose M, Martinolich L, Perrotti L, Atzori M: Muscarinic M2 and M1 receptors reduce GABA release by Ca 2+ channel modulation through activation of PI3K/Ca 2+ -independent and PLC/Ca 2+ -dependent PKC. J Neurophysiol 2007; 98: 952-965.
76. Apergis-Schoute J, Pinto A, Pare D: Muscarinic control of long-range GABAergic inhibition within the rhinal cortices. J Neurosci 2007; 27: 4061-4071.
77. Li Z, Snigdha S, Roseman AS, Dai J, Meltzer HY: Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl) -propyl]-7-f luoro-4Hbenzo[ 1,4]oxazin-3-one (AC260584) and Ndesmethylclozapine. Eur J Pharmacol 2008; 596: 89-97.
78. Kremin T, Gerber D, Giocomo LM, Huang SY, Tonegawa S, Hasselmo ME: Muscarinic suppression in stratum radiatum of CA1 shows dependence on presynaptic M1 receptors and is not dependent on effects at GABA(B) receptors. Neurobiol Learn Mem 2006; 85: 153-163.
79. Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD: M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann NY Acad Sci 1996; 777: 189-196.
80. Iversen SD: Behavioural evaluation of cholinergic drugs. Life Sci 1997; 60: 1145-1152.
81. Carlsson A: The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-186.
82. Green MF, Kern RS, Heaton RK: Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004; 72: 41-51.
83. Bymaster FP, Felder C, Ahmed S, McKinzie D: Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 2002; 1: 163-181.
84. Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3: 353-359.
85. Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE, Nathanson NM, McKinzie DL, Felder CC: Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci 2003; 17: 1403-1410.
86. Manschreck TC, Redmond DA, Candela SF, Maher BA: Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci 1999; 11: 481-489.
87. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR: The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 2004; 177: 207-216.
88. ACADIA Pharmaceuticals: ACADIA Pharmaceuticals Announces Results from ACP-Phase IIb Schizophrenia Trial. Acadia Pharmaceuticals Website. http://news.acadia-pharm.com/phoenix.zhtml?c=125180& p=irol-newsArticle- print&ID=1166151.
89. Bymaster FP, Whitesitt CA, Shannon HE, DeLapp N, Ward JS, Calligaro DO, Shipley LA, Buelke-Sam JL, Bodick NC, Farde L, Sheardown MJ, Olesen PH, Hansen KT, Suzdak PD, Swedberg MDA, Sauerberg P, Mitch CH: Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 1997; 40: 158-170.
90. Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM: Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 1998; 125: 1413-1420.
91. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC: Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165: 1033-1039.
92. Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA: Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M(4) receptor knockout mice and attenuated in muscarinic M(1) receptor knockout mice. Eur J Pharmacol 2008; 603: 147-149.
93. Clark AL, Mitchelson F: The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 1976; 58: 323-331.
94. Tucek S, Proska J: Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol Sci 1995; 16: 205-212.
95. Onali P, Adem A, Karlsson E, Olianas MC: The pharmacological action of MT-7. Life Sci 2005; 76: 1547-1552.
96. Spalding TA, Trotter C, Skjarbak N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR: Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol Pharmacol 2002; 61: 1297-1302.
97. Langmead CJ, Fry VAH, Forbes IT, Branch CL, Christopoulos A, Wood MD, Herdon HJ: Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M1 receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 2006; 69: 236-246.
98. Conn PJ, Jones CK, Lindsley CW: Subtypeselective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2009; 30: 148-155.
99. Vanover KE, Veinbergs I, Davis RE: Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. Behav Neurosci 2008; 122: 570-575.
100. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ: Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 2008; 28: 10422-10433.
101. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, Austin CA, Williams MB, Kim K, Williams R, Orton D, Brown HA, Lindsley CW, Weaver CD, Conn PJ: Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 2009; 75: 577-588.
102. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ: An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 2008; 4: 42-50.
103. Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW: Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 2008; 327: 941-953.
104. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC: Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 2008; 105: 10978-10983.
105. Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, Burstein ES: Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: Evidence for three distinct modes of receptor activation. Mol Pharmacol 2006; 70: 1974-1983.
106. Lebon G, Langmead CJ, Tehan BG, Hulme EC: Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol Pharmacol 2009; 75: 331-341.
107. van Koppen CJ, Kaiser B: Regulation of muscarinic acetylcholine receptor signaling. Pharmacol Ther 2003; 98: 197-220.
108. Rumenapp U, Asmus M, Schablowski H, Woznicki M, Han L, Jakobs KH, Fahimi-Vahid M, Michalek C, Wieland T, Schmidt M: The M3 muscarinic acetylcholine receptor expressed in HEK-293 cells signals to phospholipase D via G12 but not Gq-type G proteins: Regulators of G proteins as tools to dissect pertussis toxin-resistant G proteins in receptor-effector coupling. J Biol Chem 2001; 276: 2474-2479.
109. Akam EC, Challiss RA, Nahorski SR: G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: Dependence on agonist as well as receptor-subtype. Br J Pharmacol 2001; 132: 950-958.
110. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP: Effector pathwaydependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998; 54: 94-104.
111. Berg KA, Maayani S, Goldfarb J, Clarke WP: Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann NY Acad Sci 1998; 861: 104-110.
112. Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RJ: G Protein Coupling and signaling pathway activation by M1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther 2008; 327: 365-374.
113. Jakubik J, Bacakova L, El Fakahany EE, Tucek S: Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997; 52: 172-179.